“Unique Toxicities of Novel Myeloma Therapies: Focus on Belantamab Mafodotin, Talquetamab, and Selinexor”, Can Hematol Today, vol. 4, no. 3, pp. 24–35, Dec. 2025, doi: 10.58931/cht.2025.4379.